The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR

Lanreotide Autogel is a sustained-release aqueous gel formulation supplied in a prefilled syringe, with injection volume 4 months, with serum GH levels

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of endocrinology 2004-04, Vol.150 (4), p.473-480
Hauptverfasser:	ASHWELL, S. G, BEVAN, J. S, EDWARDS, O. M, HARRIS, M. M, HOLMES, C, MIDDLETON, M. A, LAMES, R. A
Format:	Artikel
Sprache:	eng
Schlagworte:	Acromegaly - drug therapy Adult Aged Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - adverse effects Anti-Inflammatory Agents, Non-Steroidal - blood Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Delayed-Action Preparations Endocrinopathies Female Fundamental and applied biological sciences. Psychology Humans Hypothalamus. Hypophysis. Epiphysis (diseases) Injections, Intramuscular Male Medical sciences Middle Aged Non tumoral diseases. Target tissue resistance. Benign neoplasms Octreotide - therapeutic use Peptides, Cyclic - administration & dosage Peptides, Cyclic - adverse effects Peptides, Cyclic - blood Somatostatin - administration & dosage Somatostatin - adverse effects Somatostatin - analogs & derivatives Somatostatin - blood Treatment Outcome Vertebrates: endocrinology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Lanreotide Autogel is a sustained-release aqueous gel formulation supplied in a prefilled syringe, with injection volume 4 months, with serum GH levels
ISSN:	0804-4643 1479-683X
DOI:	10.1530/eje.0.1500473